Wahlstrom Mats
SEC insider (Form 3/4/5 filer). CIK 0001459154. Director at Coherus Oncology, Inc. (CHRS) and 1 other issuer. 12 reported Form 4/5 transactions since Sep 2024; latest on Jun 5, 2026. Located in REDWOOD CITY, CA.
Companies Wahlstrom Mats has filed insider reports for
- Coherus Oncology, Inc. (CHRS): Director
- TriSalus Life Sciences, Inc. (TLSI): Director, 10% Owner
Wahlstrom Mats
CIK: 0001459154
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jun 5, 2026CHRS
Coherus Oncology, Inc.
AwardDirect30K shares- - May 15, 2026TLSI
TriSalus Life Sciences, Inc.
PurchaseDirect60K shares at avg. $2.53$152K - May 14, 2026TLSI
TriSalus Life Sciences, Inc.
AwardDirect34.2K shares- - May 14, 2026TLSI
TriSalus Life Sciences, Inc.
AwardDirect37.6K shares- - Jun 12, 2025TLSI
TriSalus Life Sciences, Inc.
AwardDirectDirector Stock Option (right to buy)
15K shares- - Jun 12, 2025CHRS
Coherus Oncology, Inc.
AwardDirectStock Option (Right to Buy)
112K shares- - May 23, 2025CHRS
Coherus BioSciences, Inc.
SaleIndirect100K shares at avg. $0.74$74K - Feb 10, 2025TLSI
TriSalus Life Sciences, Inc.
OtherIndirectSeries A Convertible Preferred Stock
44.8K shares- - Dec 17, 2024TLSI
TriSalus Life Sciences, Inc.
AwardDirect25.2K shares at avg. $3.97$100K - Nov 22, 2024TLSI
TriSalus Life Sciences, Inc.
PurchaseDirect5K shares at avg. $4.55$23K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  CHRS Coherus Oncology, Inc. | Award | 30,000 | - | $0 | Direct |
| May 15, 2026 |  TLSI TriSalus Life Sciences, Inc. | Purchase | 60,000 | $2.53 | $151,800 | Direct |
| May 14, 2026 | TLSI TriSalus Life Sciences, Inc. | Award | 34,226 | - | $0 | Direct |
| May 14, 2026 | TLSI TriSalus Life Sciences, Inc. | Award | 37,602 | - | $0 | Direct |
| Jun 12, 2025 | TLSI TriSalus Life Sciences, Inc. | Award Director Stock Option (right to buy) | 15,000 | - | - | Direct |
| Jun 12, 2025 | CHRS Coherus Oncology, Inc. | Award Stock Option (Right to Buy) | 112,000 | - | - | Direct |
| May 23, 2025 | CHRS Coherus BioSciences, Inc. | Sale | 99,988 | $0.74 | $73,881 | Indirect |
| Feb 10, 2025 | TLSI TriSalus Life Sciences, Inc. | Other Series A Convertible Preferred Stock | 44,750 | - | - | Indirect |
| Dec 17, 2024 | TLSI TriSalus Life Sciences, Inc. | Award | 25,188 | $3.97 | $99,996 | Direct |
| Nov 22, 2024 | TLSI TriSalus Life Sciences, Inc. | Purchase | 5,000 | $4.55 | $22,750 | Direct |
1-10 of 12 transactions